Today's Top Health Care Stocks to Watch: AstraZeneca plc, Clovis Oncology, Inc. and Incyte Corporation

Today's top stories in biotech and health care.

May 15, 2014 at 8:35AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for AstraZeneca (NYSE:AZN)Clovis Oncology (NASDAQ:CLVS), and Incyte Corporation (NASDAQ:INCY)

Will AstraZeneca and Clovis get an ASCO lift today?
Shares of Clovis Oncology shot up close to 9% in after-hours trading yesterday after an abstract for the company's epidermal growth factor receptor, or EGFR, inhibitor called CO-1686 was posted for the upcoming American Society of Clinical Oncology, or ASCO, meeting. CO-1686 is being studied in a mid-stage trial as a potential first-line treatment in non-small cell lung cancer, or NSCLC, patients expressing certain EGFR mutations and as a second or later-line treatment for those who become resistant to EGFR-directed therapy. Although the abstract didn't provide many details, we did learn that some patients treated with CO-1686 showed partial responses or stable disease. The company will provide a more detailed update at ASCO.

Given the limited data release, I suspect that what really got investors excited was AstraZeneca's abstract for its own EGFR inhibitor, dubbed "AZD9291." In AZD9291's early stage trial, 51% of evaluable patients showed significant reductions in tumor burden following treatment. Even more encouraging is the fact that 64% of patients with a specific EGFR mutation responded to treatment, showing that the drug may work particularly well in certain sub-populations.

Should you join the AstraZeneca or Clovis oncology party today? My take is that you might want to take a pass. Clovis shares have repeatedly shot higher in reaction to positive clinical developments in the past, only to give back their gains in short order once day traders hit the exits. Moreover, Clovis sports a $1.73 billion market cap and lacks any form of significant revenue. In this moody market, that particular combination hasn't proven to be a recipe for success, evinced by Clovis' 15% downturn year-to-date. 

Turning to AstraZeneca, I also don't see this intriguing clinical development as a buying signal either. AstraZeneca shares are already up over 35% year-to-date on the back of the highly uncertain Pfizer deal. In short, AstraZeneca could see a rapid reversal if it continues to rebuff a potential takeover. So, you might want to tread lightly with this stock for the time being. 

How far will Incyte fall today?
Shares of Incyte Corporation fell 12.77% in after-hours trading yesterday after the company posted an abstract at ASCO discussing its flagship drug Jakafi as a potential second-line pancreatic cancer treatment .  Jakafi is currently approved as a therapy for myelofibrosis, seeing sales of $69.7 million in the first-quarter of this year for this indication. Although these are decent sales numbers, Jakafi's real value lies in its ability to become a more widely applicable cancer treatment.

Investors are thus downbeat on Incyte today because the abstract notes that Jakafi failed to show a significant clinical benefit in terms of either overall survival or progression free-survival. These data stem from an ongoing mid-stage trial testing Jakafi in advanced pancreatic cancer patients that have failed first-line treatment with gemcitabine.

Looking ahead, you need to understand that Incyte is currently trading at 25 times revenue, meaning that the market is probably assigning at least some value to a label expansion for Jakafi. Now that Jakafi looks like it may not be expanded to pancreatic cancer, the market might rethink this valuation. As such, you probably don't want to try to catch this falling knife today.   

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers